Second Quarter 2021 Financial Results August 19, 2021 Safe-Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements which include, or may include, words such as "raising", "believe", "potential", "increased", "future", "remain", "growing", "expect", "foreseeable", "expected", "to be", "includes", "estimated", "assumes", "would provide", and other similar terminology. Forward-looking statements contained in this prospectus include, but are not limited to, stat ...

Financial Data and Key Metrics Changes - Revenue for the first half of 2021 grew 33% and adjusted EBITDA increased 58% compared to the same period last year [6][7] - Total company revenue for Q2 increased 26% to €204 million, with a 28.5% increase on a constant currency basis [33] - Gross margin improved by 100 basis points to 31.2%, driven by a focus on high-value solutions [37] - Adjusted operating profit margin improved by 240 basis points to 19.1% [38] - Adjusted diluted earnings per share for Q2 was €0.14, with adjusted diluted earnings per share at €0.12 [39] Business Line Data and Key Metrics Changes - High-value solutions accounted for approximately 24% of total revenue in Q2, with expectations for full-year contribution between 25% and 26% [34] - Revenue in the Biopharmaceutical and Diagnostic Solutions segment increased 23% year-over-year, with high-value solutions growing by 27% [40] - Revenue from the Engineering Segment grew by 50% to €29.1 million, benefiting from growth across all business lines [41] Market Data and Key Metrics Changes - Approximately 15% of gross revenue in Q2 was linked to the COVID-19 pandemic, with expectations for this contribution to remain consistent throughout the year [35][36] - The company experienced a 79% revenue increase in the Asia Pacific region and a 38% increase in North America during the first half of the year [94] Company Strategy and Development Direction - The company’s top three investment priorities are geographical expansion, research and development, and selected M&A to drive long-term shareholder value [9][46] - Current expansion plans in the U.S. and China are aimed at addressing high levels of customer demand, with approximately €300 million planned for these investments [25][26] - The company aims to replicate its successful investment strategy from Italy in new facilities in the U.S. and China, targeting high-value EZ-Fill products [77] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance for 2021, supported by a strong backlog of €739 million [15][60] - The company anticipates a transition to a normal business environment post-COVID, while maintaining a strong position in the vaccine space [50][56] - Management highlighted favorable macro trends, including an aging population and increasing complexity in health conditions, as drivers for long-term growth [30] Other Important Information - The company ended Q2 with cash and cash equivalents totaling €100.8 million, with free cash flow of €31.3 million [43] - The net debt ratio improved to 1 compared to 1.3 at the end of March 2021, indicating a solid financial position [44][45] Q&A Session Summary Question: Can you talk about the demand for high-value solutions and the backlog? - Management noted strong trends and a robust backlog, allowing for efficient capacity planning to meet customer demand [49][50] Question: How is COVID influencing high-value solutions sales? - Management indicated that their established relationships with major players allow for adjustments in production to meet future demands [55][56] Question: What is the current backlog compared to last year? - The backlog increased from €396 million in Q2 2020 to €739 million in Q2 2021, providing better visibility for revenue [60] Question: What is the expected tax rate for 2021? - The normalized tax rate is expected to be 24% [64] Question: What is the current average level of capacity utilization? - Capacity utilization is in the range of 80% to 85% across different production lines [72] Question: Can you discuss future M&A areas of interest? - The company is exploring opportunities in intellectual property, technologies in injection molding, and molecular diagnostics, but is not under pressure to execute any M&A [101][102]